Regenacy Pharma Earns $30 Million Series A to Advance Diabetic Neuropathy Drug

Regenacy Pharmaceuticals in Waltham, Massachusetts closed a $30 million Series A financing. The round was co-led by Cobro Ventures and Taiwania Capital Management Corporation. Other participants included 3E Bioventures Capital, Yonjin Capital, VIVA Biotech Holdings, TA YA Venture Holdings and undisclosed private investors.